Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199)

Official Title

Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (KEYNOTE-199)

Summary:

This is a study of pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel-based chemotherapy. Participants will be enrolled into one of three cohorts: Cohort 1 (participants with programmed cell death ligand 1 [PD-L1]-positive, measurable disease), Cohort 2 (participants with PD-L1 negative, measurable disease), or Cohort 3 (participants with bone-metastases and non-measurable disease)

Trial Description

Primary Outcome:

  • Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 assessed by central imaging vendor (Cohorts 1 and 2 only)
Secondary Outcome:
  • Disease Control Rate (DCR) (All Cohorts)
  • Prostate-specific Antigen (PSA) response rate (All Cohorts)
  • Percentage of participants who experience an adverse event (AE)
  • Percentage of participants who discontinue study drug due to an AE

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society